Ascendis Pharma Completes Direct Listing Transition on Nasdaq, Exchanges All ADSs for Ordinary Shares
Key Insights
Ascendis Pharma successfully transitioned from American Depositary Shares to direct listing of ordinary shares on Nasdaq Global Select Market on April 20, 2026.
All outstanding ADSs were exchanged on a one-to-one basis for ordinary shares, maintaining the same ASND ticker symbol under new CUSIP and ISIN identifiers.
The company expects the simplified listing structure to broaden global investment access and potentially facilitate inclusion in equity indexes for enhanced institutional ownership.
Ascendis Pharma A/S successfully completed its transition to a direct listing of ordinary shares on The Nasdaq Global Select Market on April 20, 2026, marking a significant milestone in the Danish biopharmaceutical company's corporate evolution. The company exchanged all outstanding American Depositary Shares (ADSs) for ordinary shares on a one-to-one basis, maintaining its established ASND ticker symbol while operating under new identification numbers.
Strategic Rationale for Direct Listing
"As we transform into a leading global biopharma company, we believe a direct listing of our ordinary shares will broaden access to global investment in Ascendis," said Scott T. Smith, Chief Financial Officer of Ascendis Pharma. The company anticipates that the simplified listing structure will enhance its market accessibility and potentially facilitate inclusion in certain equity indexes, which could result in further enhanced institutional ownership and trading liquidity for ASND shares.
Technical Implementation Details
The ordinary shares now trade under CUSIP number K08588103 and ISIN DK0060606333, replacing the previous ADS identifiers. The transition process began on April 8, 2026, when Ascendis announced its plans for the mandatory exchange, with the last trading day for ADSs occurring on April 17, 2026. By April 20, 2026, the company had successfully exchanged all outstanding ADSs for ordinary shares.
Company Background and Technology Platform
Ascendis Pharma operates as a global biopharmaceutical company focused on applying its innovative TransCon (search) technology platform to address unmet medical needs. The company is guided by core values of Patients, Science, and Passion, following an algorithm for product innovation to develop new therapies with best-in-class potential. Headquartered in Copenhagen, Denmark, Ascendis maintains additional facilities across Europe and the United States.
The company has made frequently asked questions related to the listing transition available on the Investors & News section of its website to assist stakeholders in understanding the implications of the structural change. This direct listing represents part of Ascendis' broader strategic positioning as it continues to advance its TransCon (search) technology platform in the competitive biopharmaceutical landscape.